BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment

BH3 mimetics are promising drugs for hematologic malignancies that trigger cell death by promoting the release of proapoptotic BCL2 family members from antiapoptotic proteins. Multiple myeloma is considered to be a disease dependent mainly on MCL1 for survival, based mostly on studies using cell lin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2018-12, Vol.132 (25), p.2656-2669
Hauptverfasser:	Gomez-Bougie, Patricia, Maiga, Sophie, Tessoulin, Benoît, Bourcier, Jessie, Bonnet, Antoine, Rodriguez, Manuel S., Le Gouill, Steven, Touzeau, Cyrille, Moreau, Philippe, Pellat-Deceunynck, Catherine, Amiot, Martine
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology bcl-2 Homologous Antagonist-Killer Protein - genetics bcl-2 Homologous Antagonist-Killer Protein - metabolism Biomimetic Materials - chemistry Biomimetic Materials - pharmacology Cell Line, Tumor Humans Multiple Myeloma - drug therapy Multiple Myeloma - genetics Multiple Myeloma - metabolism Multiple Myeloma - pathology Myeloid Cell Leukemia Sequence 1 Protein - genetics Peptide Fragments Proto-Oncogene Proteins Proto-Oncogene Proteins c-bcl-2 - genetics Proto-Oncogene Proteins c-bcl-2 - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!